The Effectiveness of Phytotherapy in SARS-COV2(COVID-19)

NCT ID: NCT04851821

Last Updated: 2023-01-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-01-04

Study Completion Date

2021-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Quercetin is one of the flavonoids. Quercetin as well as rutin are recognized to be among the most active of the flavonoids. It is to quercetin that several medicinal plants, including ginkgo and St. John's Wort, owe part of their therapeutic effects. Often combined with vitamin C in supplements, it improves absorption by the body and delays its elimination.

Quercetin is extracted from a variety of plant sources, including the onion peel and seeds and pods of Dimorphandra mollis, a tree in the legume family native to South America.

At present, there is no scientific data to demonstrate the effectiveness of herbal medicine, regardless of the plant, to prevent or treat COVID-19. On the other hand, some plant-based food supplements have anti-inflammatory or immunomodulatory properties that may disrupt inflammatory defense mechanisms useful in fighting infections, and in particular against COVID-19.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Type of study: a randomized, double-blind study using the Quercetine in the treatment of patients with SARS COV2 (covid-19) Quercetin is extracted from a variety of plant sources, including the onion peel and the seeds and pods of Dimorphandra mollis, a legume tree native to South America.

Although we are far from knowing everything about quercetin, its antioxidant, anti-inflammatory, and antihistamine (antiallergic) properties have been observed in numerous in vitro and animal studies.

History on quercetin In 1937, Albert Szent-Gyorgyi received a Nobel Prize for discovering vitamin C and flavonoids, as well as for exploring their biochemical properties. Originally, he gave the flavonoids the name "vitamin P" because of their effectiveness in reducing the permeability of blood vessels. This name was abandoned when it was realized that these substances were not really vitamins.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

a Randomized Double-blind Study Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) PHYTOTHERAPIE

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Quercetix group

Each patient included, after signing the consent, will have a treatment for ten days: one tablet twice a day 30 minutes before the meal.

Group Type EXPERIMENTAL

Quercetin

Intervention Type DRUG

Each patient included, after signing the consent, will have a treatment for ten days: one tablet times three per day 30 minutes before the meal.

Placebo Group

Each patient included, after signing the consent, will have a treatment for ten days: one tablet twice a day 30 minutes before the meal.

Group Type PLACEBO_COMPARATOR

Quercetin

Intervention Type DRUG

Each patient included, after signing the consent, will have a treatment for ten days: one tablet times three per day 30 minutes before the meal.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Quercetin

Each patient included, after signing the consent, will have a treatment for ten days: one tablet times three per day 30 minutes before the meal.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

PLACEBO

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* all patients attending the emergency department for influenza-like illness.
* Being over 18 years old

Exclusion Criteria

* Any patient requiring admission
* Non-consenting patients
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hôpital Universitaire Sahloul

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Riadh Boukef

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Riadh Boukef, professor

Role: PRINCIPAL_INVESTIGATOR

CHU Sahloul, Sousse, Tunisia

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Riadh Boukef

Sahloul, Sousse Governorate, Tunisia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Tunisia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Quercetix

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Quercetin in Coronary Artery By-pass Surgery
NCT04907253 ACTIVE_NOT_RECRUITING PHASE2
Palmitic Acid and Human Microvascular Function
NCT06683534 NOT_YET_RECRUITING PHASE2